Cover Image
市場調查報告書

體外診斷 (IVD) 的中國市場

IVD in China

出版商 Kalorama Information 商品編碼 333253
出版日期 內容資訊 英文 264 Pages
訂單完成後即時交付
價格
Back to Top
體外診斷 (IVD) 的中國市場 IVD in China
出版日期: 2015年06月11日 內容資訊: 英文 264 Pages
簡介

有10億以上人口的中國,過去10年,在實質GDP的年複合成長率中帶動全球經濟,在體外診斷 (IVD) 市場中也成為接著美國、西歐各國、日本的已開發國家的規模。中國是亞太地區最大的臨床試驗所市場,之一,在IVD市場主要10個國家中最快成長。

本報告提供中國的IVD市場現狀與至2024年的預測、各市場區隔的市場規模與成長預測、SWOT分析,及參與企業簡介等彙整資料。

第1章 摘要整理

第2章 發展中國家的醫療及診斷藥的簡介:中國的情形

  • 背景
  • 人口趨勢與疾病人口統計
  • 肥胖
  • 糖尿病
  • 癌症
  • 過敏及氣喘
  • 心血管疾病
  • 新興病毒及疾病
  • 抗生素抗藥性
  • 臨床實驗室檢驗
  • 市場細分領域的機會
  • 中國的未來的經濟發展
  • 金磚四國指標:中國的IVD市場
  • IVD投資

第3章 中國的IVD市場相關SWOT分析

  • 簡介
  • 促進優勢:市場成長的情形
    • 政府對新興中國醫療市場的輔助
    • 歐美風格的醫藥品
    • 有氣勢的生物科技產業
    • 研究受託和先進技術
    • 科學家的回鄉
    • 醫院部門的擴大
    • 臨床試驗所的擴大
  • 弱點:市場成功及進入障礙等因素
    • 東洋醫學
    • 醫院資源的規定
    • 文化和商務環境
    • 智慧財產權問題
    • 品質及安全性問題
    • 醫療保險
    • 法律規章:產品認證和臨床實驗
    • 法律規章:醫療服務成本管理
    • 流通問題
  • 機會:地方醫療及技術夥伴關係
  • 威脅:國內競爭和政府的政策

第4章 中國IVD市場規模

  • 簡介
  • 市場
  • 整體市場
    • 免疫檢測
    • 臨床化學
    • 血液學
    • 照護現場
    • 分子
    • 尿液檢查
    • 其他IVD檢驗

第5章 中國的產業及企業活動

  • 簡介
  • 中國市場領導
  • 國際IVD企業
  • 中國國內的IVD企業

圖表

目錄
Product Code: KLI5586455

With a population of more than 1 billion, China is the world's largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro diagnostics (IVD) market, China trails only the populous, developed markets of the United States, western European countries, and Japan. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets.

This report places China and its IVD market in context with the developing world in terms of diseases, economic and healthcare system development, and other key metrics related to health expenditures and diagnostics. China as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and India; collectively with China referred to as “BRIC” nations. China and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, obesity and diseases of aging.

IVD in China presents current analysis of the Chinese IVD industry and provides forecasts to 2024. The report takes an in-depth look at the market, providing data on the size and growth of the total Chinese market as well as on the following IVD in China market segments:

  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Point of Care/OTC
  • Molecular
  • Urinalysis
  • Other IVD Tests

IVD in China presents the main issues and trends affecting this market, influencing its move into the future. Some of these include:

  • The Future of Chinese Economic Growth
  • Chinese Healthcare Reform and Hospital Infrastructure
  • Market Barriers - Regulation, Policy and Distribution
  • Market Segment Opportunities
  • BRIC Metrics - Chinese IVD Market in Context
  • IVD Spending
  • Strengths - Conditions That Support Market Growth
  • Weaknesses - Factors That Pose Barriers to Market Success and Entry
  • Opportunities - Rural Healthcare and Technology Partnerships
  • Threats - Domestic Competition and Government Policy

The report provides detailed information regarding the IVD industry and company activity in China. Recent activity of international IVD Companies in China is presented. Companies discussed include:

  • Abbott Laboratories
  • Affymetrix, Inc.
  • ALERE
  • Arkray
  • Axis-Shield, plc
  • Beckman Coulter, Inc./Danaher
  • Becton, Dickinson & Co.
  • Biohit Oy
  • bioMérieux, Inc.
  • Bio-RAD Laboratories, Inc.
  • Danaher Corp.
  • Gen-Probe, Inc.
  • Hologic, Inc.
  • Horiba Medical
  • Instrumentation Laboratory
  • IRIS International, Inc.
  • Laboratory Corporation of America
  • Life Technologies Corporation
  • Luminex Corporation
  • MedMira
  • Myriad Genetics
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Phadia AB
  • Promega Corporation
  • QIAGEN N.V.
  • Radiometer A/S
  • Roche
  • Siemens
  • SuperNova Diagnostics, Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific

Recent activity of Chinese IVD companies is discussed as well. Companies examined include:

  • Autobio Group
  • BioSino Bio-Technology and Science, Inc.
  • CapitalBio Corporation
  • Caretium Medical Instruments
  • Chemtron Biotech Co., Ltd.
  • China Health Labs & Diagnostics, Ltd.
  • Daan Gene Co., Ltd.
  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Hai Kang Life Corporation
  • Shanghai Kehua Bio-engineering
  • Beijing Leadman Biochemistry Co., Ltd.
  • Mindray Medical International, Ltd.

Information for this report was gathered from a wide variety of published sources including company reports, catalogs, materials and public filings; government documents; trade journals; newspapers and business press; analysts' reports and other sources. Interviews with industry experts were conducted to capture the perspectives from market participants' point of view and assess trends, and form the basis of the forecasting and competitive analysis. Sales estimates are provided for the historic 2009 to 2014 period and forecasts are provided through 2024. The size of each market segment refers to manufacturers' revenues in U.S. dollars.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Major Findings of the Report
  • China in Context - A Developing Economy with Developed World Problems
  • Demographic Aging
  • Disease Drivers
  • Infectious Disease Threats
  • Chinese Economy
  • IVD Market in the BRIC Countries
  • IVD Market in China
  • Chinese Healthcare Reform and Hospital Infrastructure
  • Market Barriers - Regulation, Policy and Distribution
  • Regulation and Policy Challenges for International Companies
  • Distribution in China

TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT

  • Background
  • Population Trends and Disease Demographics
  • Obesity
  • Disease Trends
  • Diabetes
  • Cancer
  • Allergy and Asthma
  • Cardiovascular Disease
  • Emerging Viruses and Diseases
  • Antimicrobial Drug Resistance
  • Clinical Lab Tests
  • Types of Tests
  • Venues for Test Usage
  • Market Segment Opportunities
  • Point-of-Care (POC) Testing
  • Core Lab Tests
  • Molecular Assays
  • Hematology
  • Coagulation
  • Microbiology
  • Tests Used in Blood Banking
  • Histology and Cytology
  • The Future of Chinese Economic Growth
  • Strong Capital Markets and M&A Activity
  • Rising Standards of Living
  • Corruption and Bribery
  • BRIC Metrics - Chinese IVD Market in Context
  • Available Markets - Urban Populations in BRIC Countries
  • Paying for Healthcare - Government Expenditures and the Culture of Spending
  • Healthcare Capacities in BRIC Nations - A Work in Progress
  • IVD Spending
  • Will China Capture the IVD Industry?

THREE: CHINA IVD SWOT ANALYSIS

  • Introduction
  • Strengths - Conditions That Support Market Growth
  • Government Support of the Emerging Chinese Healthcare Market
  • Western-Style Pharmaceuticals
  • Thriving Biotech Industry
  • Contract Research and High Technology
  • Returning Scientists
  • Growing Hospital Sector
  • Expanding Clinical Labs
  • Weaknesses - Factors That Pose Barriers to Market Success and Entry
  • Traditional Chinese Medicine
  • Resource Constraints in Hospitals
  • Culture and Business Environment
  • Intellectual Property Issues
  • Quality and Safety Concerns
  • Healthcare Insurance
  • Regulation - Product Approval and Clinical Trials
  • Regulation - Healthcare Service Cost Controls
  • Distribution Challenges
  • Opportunities - Rural Healthcare and Technology Partnerships
  • Threats - Domestic Competition and Government Policy
  • Domestic Competition
  • Government Policy and Price Setting

FOUR: CHINA IVD MARKET SIZE

  • Introduction
  • The Market
  • Total Chinese IVD Market
  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Point of Care/OTC
  • Molecular
  • Urinalysis
  • Other IVD Tests

FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA

  • Introduction
  • Market Leaders in China
  • International IVD Companies - Recent Activity
  • Abbott Laboratories
  • Affymetrix, Inc.
  • ALERE
  • Arkray
  • Axis-Shield, plc
  • Beckman Coulter, Inc./Danaher
  • Becton, Dickinson & Co.
  • Biohit Oy
  • bioMérieux, Inc.
  • Bio-RAD Laboratories, Inc
  • Danaher Corp.
  • Gen-Probe, Inc.
  • Hologic, Inc.
  • Horiba Medical
  • Instrumentation Laboratory
  • IRIS International, Inc.
  • Laboratory Corporation of America
  • Life Technologies Corporation
  • Luminex Corporation
  • MedMira
  • Myriad Genetics
  • Novartis Diagnostics
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Phadia AB
  • Promega Corporation
  • QIAGEN N.V.
  • Radiometer A/S
  • Roche
  • Siemens
  • SuperNova Diagnostics, Inc.
  • Sysmex Corp.
  • Thermo Fisher Scientific
  • Chinese IVD Companies - Recent Activity
  • Autobio Group
  • BioSino Bio-Technology and Science, Inc.
  • CapitalBio Corporation
  • Caretium Medical Instruments
  • Chemtron Biotech Co., Ltd.
  • China Health Labs & Diagnostics, Ltd.
  • Daan Gene Co., Ltd.
  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Hai Kang Life Corporation
  • Shanghai Kehua Bio-engineering
  • Beijing Leadman Biochemistry Co., Ltd.
  • Mindray Medical International, Ltd.

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Exhibit 1-1: Global Map of China
  • Exhibit 1-2: Industrial Map of China
  • Table 1-1: BRIC IVD Markets by Country, 2014-2019
  • Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014

TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT

  • Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries(2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World)
  • Table 2-2: Selected Worldwide Disease Statistics, 2014
  • Exhibit 2-1: Diabetes Population by Country, 2015
  • Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China)
  • Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015
  • Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
  • Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
  • Exhibit 2-4: Chinese GDP per Capita by Province, 2012
  • Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
  • Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
  • Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, SouthKorea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy)
  • Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries(Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy,Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand,
  • Turkey, United Kingdom, United States, Vietnam)
  • Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014(United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India)
  • Table 2-10: BRIC IVD Markets by Country, 2014-2019
  • Table 2-11: Selected Made-in-China Lab Supplies

THREE: CHINA IVD SWOT ANALYSIS

  • Exhibit 3-1: Chinese Hospitals by Tier
  • Exhibit 3-2: Hospital Count by Certification Status, 2014
  • Exhibit 3-3: Ethnolinguistic Map of China
  • Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
  • Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
  • Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality

FOUR: CHINA IVD MARKET SIZE

  • Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other)
  • Table 4-1: Total IVD Sales in China, 2014-2024
  • Exhibit 4-2: Total IVD Sales in China, 2014-2024
  • Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
  • Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
  • Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
  • Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
  • Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
  • Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
  • Table 4-5: Immunoassay Sales in China, 2014-2024
  • Exhibit 4-6: Immunoassay Sales in China, 2014-2024
  • Table 4-6: Clinical Chemistry Sales in China, 2014-2024
  • Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
  • Table 4-7: Hematology Sales in China, 2014-2024
  • Exhibit 4-8: Hematology Sales in China, 2014-2024
  • Table 4-8: Point of Care/OTC Sales in China, 2014-2024
  • Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
  • Exhibit 4-10: Selected Point of Care/OTC Products Sold in China
  • Table 4-9: Molecular Test Sales in China, 2014-2024
  • Exhibit 4-11: Molecular Test Sales in China, 2014-2024
  • Table 4-10: Urinalysis Test Sales in China, 2014-2024
  • Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
  • Table 4-11: Other IVD Test Sales in China, 2014-2024
  • Exhibit 4-13: Other IVD Test Sales in China, 2014-2024

FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA

  • Table 5-1: Leading Global IVD Companies in China
  • Table 5-2: Leading Domestic IVD Companies in China
  • Table 5-3: Leading Chinese IVD Companies
Back to Top